Benzinga's Top Pre-Market Losers
September 10, 2013 at 08:14 AM EDT
Neurocrine Biosciences (NASDAQ: NBIX ) shares dropped 27.25% to $12.15 in pre-market trading after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia. ChemoCentryx (NASDAQ: CCXI ) dipped 15.25% to $7 in the pre-market session after the company announced top-line interim results for
